Phaseline

Targets › P4HTM

P4HTM (Transmembrane prolyl 4-hydroxylase): drug programs, companies and trials

1 program from 1 company in 5 trials: 2 Phase 3, 2 Phase 1, 1 Phase 4; Genitourinary, Hematology, Psychiatry; next expected readout Oct 2027.

Catalyzes the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates HIF1A at 'Pro-402' and 'Pro-564'. May function as a cellular oxygen sensor and, under normoxic conditions, may target HIF through the hydroxylation for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. (UniProt, Q9NXG6)

Open in Phaseline: the race on P4HTM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstellasRoxadustat
Hypoxia-inducible factor prolyl hydroxylase inhibitor
EGLN2, P4HTM, EGLN1, EGLN3Phase 3Chronic Kidney Disease; Dialysis; Complications; Perioperative Anemia; Kidney Failure, Chronic …Oct 2027

Conditions

Chronic Kidney Disease (1) Dialysis; Complications (1) Perioperative Anemia (1) Kidney Failure, Chronic (1) Kidney Failure,Chronic (1)

Modalities

small molecule (1)

Companies

Astellas (1)

Related targets

EGLN2 (1) EGLN1 (1) EGLN3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.